Natera vs. CareDx: cfDNA Patent Infringement Battle in Transplant Diagnostics

Case Overview

When two of the most prominent names in transplant diagnostics collide in federal court over cell-free DNA (cfDNA) testing patents, the entire precision medicine industry takes notice. Natera, Inc. filed suit against CareDx, Inc. on May 13, 2022, in the Delaware District Court (Case No. 1:22-cv-00642), asserting patent infringement related to cfDNA-based organ transplant monitoring technology. The case, which closed on March 12, 2025, was ultimately consolidated with two related actions into a single lead proceeding — a procedural move carrying significant strategic implications for how multi-patent cfDNA infringement disputes are managed at the district court level.

At stake: CareDx’s flagship products AlloSure, AlloSeq, KidneyCare, and HeartCare — commercially critical diagnostics tools used in post-transplant patient monitoring. This case represents a defining moment in **cfDNA patent infringement litigation**, establishing competitive battle lines that will shape IP strategy across the liquid biopsy and transplant diagnostics sectors for years to come.

The Parties

The Patent at Issue

The asserted patent is **US11111544B2** (application number US16/823127), covering cfDNA-based detection methodologies central to transplant organ surveillance. The patent’s claims broadly address quantitative analysis of donor-derived cell-free DNA in transplant recipients — a technically sophisticated and commercially valuable claim space.

• • US11111544B2 — cfDNA-based detection methodologies for transplant organ surveillance.

The Verdict & Legal Analysis

Outcome

The -642 action was closed on March 12, 2025, through a stipulated consolidation rather than a merits-based verdict. Pursuant to FRCP 42(a), this case merged with Case Nos. 1:22-cv-00038 and a related -641 action into a unified proceeding under the lead -038 docket. No damages amount has been disclosed in connection with this procedural resolution, and the substantive infringement claims remain live under the consolidated lead case.

This outcome is not a dismissal or settlement — it is a strategic procedural alignment that concentrates the parties’ disputes into a single, coordinated proceeding.

Legal Significance

The consolidation of the -038, -641, and -642 actions is itself a legally significant development. For practitioners, it signals:

1. Multi-patent assertion strategies in platform technology sectors (like cfDNA diagnostics) are increasingly litigated as unified campaigns rather than isolated infringement suits.
2. FRCP 42(a) consolidation can serve as both a judicial efficiency tool and a strategic lever — plaintiffs may structure multi-case filings anticipating eventual consolidation around a lead patent.
3. The Delaware District Court continues to accommodate complex, multi-action patent dockets efficiently, reinforcing its status as the preferred venue for high-stakes IP litigation.

The substantive legal questions — including claim construction of US11111544B2, infringement analysis of CareDx’s dd-cfDNA methodologies, and any validity challenges — remain pending in the lead -038 proceeding.